Evidence map›Paper›PMID 36613859›Full record

ArticleInternational journal of molecular sciences2022

Impact on the Clinical Evolution of Patients with COVID-19 Pneumonia and the Participation of the

María Elena Soto, Giovanny Fuentevilla-Álvarez, Adrián Palacios-Chavarría, Rafael Ricardo Valdez Vázquez, Héctor Herrera-Bello, Lidia Moreno-Castañeda, Yazmín Estela Torres-Paz, Nadia Janet González-Moyotl, Idalia Pérez-Torres, Alfredo Aisa-Alvarez and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

María Elena SotoDepartment of Immunology, Instituto Nacional de Cardiología "Ignacio Chávez", Juan Badiano No. 1. Col. Sección XVI., México City 14380, Mexico.ORCID 0000-0003-1332-2888
Giovanny Fuentevilla-ÁlvarezDepartment of Physiology, Instituto Nacional de Cardiología "Ignacio Chávez", Juan Badiano No. 1. Col. Sección XVI., México City 14380, Mexico.ORCID 0000-0002-1819-8444
Adrián Palacios-ChavarríaCritical Care Unit of the Temporal COVID-19 Unit, Citibanamex Center Av. del Conscripto 311, Lomas de Sotelo, Hipódromo de las Américas, Miguel Hidalgo, México City 11200, Mexico.ORCID 0000-0003-2299-1581
Rafael Ricardo Valdez VázquezCritical Care Unit of the Temporal COVID-19 Unit, Citibanamex Center Av. del Conscripto 311, Lomas de Sotelo, Hipódromo de las Américas, Miguel Hidalgo, México City 11200, Mexico.
Héctor Herrera-BelloCritical Care Unit of the Temporal COVID-19 Unit, Citibanamex Center Av. del Conscripto 311, Lomas de Sotelo, Hipódromo de las Américas, Miguel Hidalgo, México City 11200, Mexico.
Lidia Moreno-CastañedaCritical Care Unit of the Temporal COVID-19 Unit, Citibanamex Center Av. del Conscripto 311, Lomas de Sotelo, Hipódromo de las Américas, Miguel Hidalgo, México City 11200, Mexico.
Yazmín Estela Torres-PazDepartment of Physiology, Instituto Nacional de Cardiología "Ignacio Chávez", Juan Badiano No. 1. Col. Sección XVI., México City 14380, Mexico.
Nadia Janet González-MoyotlDepartment of Physiology, Instituto Nacional de Cardiología "Ignacio Chávez", Juan Badiano No. 1. Col. Sección XVI., México City 14380, Mexico.ORCID 0000-0003-0672-5048
Idalia Pérez-TorresDepartment of Genetic, Hospital Infantil de México "Federico Gómez", Doctor Márquez 162, Col. Doctores, México City 06720, Mexico.
Alfredo Aisa-AlvarezCritical Care Unit of the Temporal COVID-19 Unit, Citibanamex Center Av. del Conscripto 311, Lomas de Sotelo, Hipódromo de las Américas, Miguel Hidalgo, México City 11200, Mexico.
Linaloe Manzano-PechDepartment of Cardiovascular Biomedicine, Instituto Nacional de Cardiología "Ignacio Chávez", Juan Badiano No. 1. Col. Sección XVI., México City 14380, Mexico.
Israel Pérez-TorresDepartment of Cardiovascular Biomedicine, Instituto Nacional de Cardiología "Ignacio Chávez", Juan Badiano No. 1. Col. Sección XVI., México City 14380, Mexico.ORCID 0000-0001-6510-2954
Claudia Huesca-GómezDepartment of Physiology, Instituto Nacional de Cardiología "Ignacio Chávez", Juan Badiano No. 1. Col. Sección XVI., México City 14380, Mexico.
Ricardo GamboaDepartment of Physiology, Instituto Nacional de Cardiología "Ignacio Chávez", Juan Badiano No. 1. Col. Sección XVI., México City 14380, Mexico.ORCID 0000-0001-9102-4240
Instituto Nacional de Cardiología · MXCentro Médico ABC · MXHospital Infantil de México Federico Gómez · MX

Funding

Consejo Nacional de Ciencia y Tecnología 312167
6 · The paper itself

Abstract

In patients with severe pneumonia due to COVID-19, the deregulation of oxidative stress is present. Nuclear erythroid factor 2 (NRF2) is regulated by KEAP1, and NRF2 regulates the expression of genes such as NFE2L2-KEAP1, which are involved in cellular defense against oxidative stress. In this study, we analyzed the participation of the polymorphisms of NFE2L2 and KEAP1 genes in the mechanisms of damage in lung disease patients with SARS-CoV-2 infection. Patients with COVID-19 and a control group were included. Organ dysfunction was evaluated using SOFA. SARS-CoV-2 infection was confirmed and classified as moderate or severe by ventilatory status and by the Berlin criteria for acute respiratory distress syndrome. SNPs in the gene locus for NFE2L2, rs2364723C>G, and KEAP1, rs9676881A>G, and rs34197572C>T were determined by qPCR. We analyzed 110 individuals with SARS-CoV-2 infection: 51 with severe evolution and 59 with moderate evolution. We also analyzed 111 controls. Significant differences were found for rs2364723 allele G in severe cases vs. controls (p = 0.02); for the rs9676881 allele G in moderate cases vs. controls (p = 0.04); for the rs34197572 allele T in severe cases vs. controls (p = 0.001); and in severe vs. moderate cases (p = 0.004). Our results showed that NFE2L2 rs2364723C>G allele G had a protective effect against severe COVID-19, while KEAP1 rs9676881A>G allele G and rs34197572C>T minor allele T were associated with more aggressive stages of COVID-19.

Indexed as

COVID-19Kelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2Genetic Predisposition to DiseaseHumansSARS-CoV-2KEAP1 protein, humanKelch-Like ECH-Associated Protein 1NFE2L2 protein, humanNF-E2-Related Factor 2COVID-19inflammationKEAP1NFE2L2pathogenesisSARS-CoV-2single nucleotide polymorphism

Identifiers

PMID36613859
PMCPMC9820269
OpenAlexW4313260860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.